Health News Review

Health News Review
Share

Health News Review

 •  December 5

Our Review Summary The Guardian covers a new phase III clinical trial of erenumab, a drug injected monthly, designed to reduce the frequency of painful migraines. The piece does a good job putting the results into context and even compares those findings to the placebo group, giving them a more transparent and helpful context. However, readers...

Health News Review

 •  October 19

Our Review Summary This story focuses on a family tragedy—three young boys in a single family with a fatal genetic disorder called Duchenne muscular dystrophy—and the family’s hope that an experimental drug, which the three boys have been taking as part of a clinical trial, will receive FDA approval later this month. The story is filled with...

Health News Review

 •  August 30

Our Review Summary People with heart disease and cancer, along with physicians, are bombarded almost daily with the onslaught of novel, eye-poppingly expensive, and ever “promising” new ways to treat or prevent these life-threatening disorders. Because their benefits and potential harms are so often barely known, and because their impacts are...

Health News Review

 •  April 7

Last week the FDA approved two more pricey new drugs labeled “breakthroughs” by some news outlets. Ocrevus, which treats a type of multiple sclerosis, comes with an annual price tag of $65,000 while Dupixent, a drug for severe eczema, costs $37,000. Yet so far, the price of those “breakthroughs” has not captured widespread national attention or...

Health News Review

 •  March 23

Our Review Summary This case series involving 25 patients looked at the effect of pembrolizumab on patients with pleural mesothelioma (a cancer that develops on the lining of the lungs) and found what appears to be an improved level of tolerance. By omitting many important details of the study, it’s very hard to determine what sort of advantage...

Health News Review

 •  February 20

Our Review Summary The US Food and Drug Administration just approved a new drug to treat psoriasis, a common skin condition that can form thick, silvery scales and itchy, dry, red patches. Siliq (brodalumab) is mainly intended for patients who don’t respond to other forms of treatment, like anti-inflammatory topical medications and light therapies....